Table 2.
Biomarker Result | Patients Eligible, N (%) |
---|---|
FDA-approved therapy Received Therapy |
33 (21.8) 26 (17.2) |
Targeted clinical trial Enrolled in Trial |
27 (17.9) 1 (0.7) |
Off-label therapy | 9 (6.0) |
Received Therapy | 2 (1.3) |
Therapeutic resistance | 20 (13.2) |
Germline implications | 15 (10.0) |
None | 64 (42.4) |